Unique ID issued by UMIN | UMIN000029576 |
---|---|
Receipt number | R000033784 |
Scientific Title | Efficacy and safety of chemotherapy after PD-1 inhibitors in patients with non-small cell lung cancer: a retrospective multi-institutional analysis (WJOG10217L) |
Date of disclosure of the study information | 2017/10/20 |
Last modified on | 2021/10/08 17:13:58 |
Efficacy and safety of chemotherapy after PD-1 inhibitors in patients with non-small cell lung cancer: a retrospective multi-institutional analysis (WJOG10217L)
chemotherapy after PD-1 inhibitors
Efficacy and safety of chemotherapy after PD-1 inhibitors in patients with non-small cell lung cancer: a retrospective multi-institutional analysis (WJOG10217L)
chemotherapy after PD-1 inhibitors
Japan |
advanced non-small cell lung cancer
Medicine in general | Pneumology | Hematology and clinical oncology |
Malignancy
NO
The objective of this retrospective study is to investigate the efficacy and safety of chemotherapy after PD-1 inhibitors in patients with non-small cell lung cancer
Safety,Efficacy
Overall response rate of cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1
Progression-free survival, overall survival and safety of cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1
Observational
Not applicable |
Not applicable |
Male and Female
1. Histologically or cytologically confirmed NSCLC
2. Stage III, IV or recurrence after curative radiotherapy or surgery according to the seventh edition of the TNM classification
3. Previously treated with cytotoxic chemotherapy as a first-line
1) Study arm: treated with nivolumab or pembrolizumab as a second-line and subsequently treated with cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1 as a third-line between December 1, 2015 and July 31, 2017
2) Control arm: treated with cytotoxic chemotherapy including docetaxel (with or without ramucirumab), pemetrexed or S-1 as a second-line between April 1, 2014 and July 31, 2017
None
240
1st name | Ryoji / Hidetoshi |
Middle name | |
Last name | Kato / Hayashi |
Kindai University Faculty of Medicine
Department of Medical Oncology
589-8511
377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan
072-366-0221
kato8560@gmail.com
1st name | Shinichiro |
Middle name | |
Last name | Nakamura |
West Japan Oncology Group
WJOG datacenter
556-0016
Namba Plaza Bldg. 304-1-5-7, Motomachi Naniwa-ku, Osaka 556-0016 JAPAN
06-6633-7400
datacenter@wjog.jp
West Japan Oncology Group
None
Self funding
Department of Medical Oncology, Kindai University Faculty of Medicine
377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan
072-366-0221
kato8560@gmail.com
NO
2017 | Year | 10 | Month | 20 | Day |
Partially published
1626
Completed
2017 | Year | 10 | Month | 06 | Day |
2017 | Year | 11 | Month | 02 | Day |
2017 | Year | 11 | Month | 20 | Day |
2019 | Year | 06 | Month | 30 | Day |
This retrospective study will be performed based on the patient's clinical records.
2017 | Year | 10 | Month | 16 | Day |
2021 | Year | 10 | Month | 08 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033784